Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study will compare aggressive antiarrhythmic therapy to catheter ablation for
ventricular tachycardia in patients who have suffered prior myocardial infarction. The
purpose of this study is to evaluate the optimal management of patients presenting with
recurrent VT and receiving ICD therapy in spite of first-line antiarrhythmic drug therapy.
The hypothesis is catheter ablation is superior to aggressive antiarrhythmic drug therapy for
recurrent VT.
Phase:
Phase 4
Details
Lead Sponsor:
John Sapp
Collaborators:
Abbott Medical Devices Biosense Webster, Inc. Canadian Institutes of Health Research (CIHR) St. Jude Medical